| abstract |
The present invention relates to a compound of formula (1). The present invention also relates to a process for the preparation of the compound of formula (I), a pharmaceutical composition containing the same, and a method for the use thereof, in particular for the control of autoimmune diseases.n n n <Formula 1>n n n n n n n n In the formula,n n n R 1 and R 2 are each independently C 1-6 alkyl, C 3-6 alkenyl, C 3-6 cycloalkylC 1-3 alkyl or C 3-6 cycloalkyl, each of which is optionally 1 to 3 May be substituted with a halogen atom;n n n R 3 is isoxazolidin-2-ylcarbonyl or tetrahydroisoxazine-2-ylcarbonyl, wherein the rings are each optionally substituted with one hydroxy group;n n n Q is -CO- or -C (R 4 ) (R 5 )-, wherein R 4 is a hydrogen atom or C 1-4 alkyl and R 5 is a hydrogen atom or a hydroxy group;n n n Ar is a 5-10 membered aromatic ring system in which up to 4 ring atoms can independently be heteroatoms selected from nitrogen, oxygen and sulfur, and the ring system is optionally substituted with one or more substituents as defined herein. |